Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENT-VSEL study of intramyocardial autologous CD133+ bone marrow cells for refractory angina
2011-005435-98Phase 2Completed
- Sponsor
- Medical University of Silesia
- Start
- Feb 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous CD133+ bone marrow-derived cells in stable angina, angina pectoris and cardiac ischemia (2 arms), sponsored by Medical University of Silesia. Primary endpoint: Change in myocardial perfusion. Started Feb 2012; status: completed.
02
Drugs
autologous CD133+ bone marrow-derived cells
03
Conditions
stable anginaangina pectoriscardiac ischemia
Beyond the preview
Go deeper on 2011-005435-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005435-98.